EDGAR·FLOW

Passage BIO, Inc. — Form 8-K

Filed November 18, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 92/100
What the filing says
On November 12, 2026, Passage BIO, Inc. received notice of failure to satisfy continued listing standards, triggering a delisting proceeding. The filing does not specify which exchange issued the notice, the specific listing rule violated, or remediation timeline. This represents a critical corporate event for the $25.4M market-cap company.
Why this rating

Delisting is existential threat to small-cap public company; directly threatens market access, liquidity, and investor base regardless of underlying business health.

Extracted items
Tradability signal
NO TRADE

No trade: only ~$51k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
before filing · preread
$4.01 ▼ 0.74%
at our read · unknown
$4.04
+10 min · unknown
$4.04 ▲ 0.00%
+30 min · unknown
$4.04 ▲ 0.00%
+1 hr · unknown
$4.04 ▲ 0.00%
+4 hrs · unknown
$3.98 ▼ 1.36%

The stock had already moved +0.75% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ PASG · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.